US Bio Executive Purchases 900,000 Shares in Four Days

Kevin Tang, a director of Canadian biopharma company Aurinia Pharmaceuticals Inc. (AUPH), disclosed that he acquired approximately 901,000 additional common shares of the company in open-market transactions on February 27 and March 2–3. The shares were purchased indirectly through a limited partnership he controls, at prices ranging from $13.90 to $14.33 per share, bringing his indirect holdings to over 12 million shares. The total purchase amount was about $12.7 million (approximately KRW 17 billion).

Aurinia has continued its positive performance trend, driven by expanding sales of its lupus nephritis therapy LUPKYNIS. In the third quarter of 2025, the company achieved double-digit year-over-year revenue growth and raised its full-year sales guidance. Recent coverage by U.S. financial and investment media highlights that, as Aurinia strengthens its position in the lupus nephritis market, its stock is forming bullish patterns.

Aurinia, a Canadian biotech firm, develops and markets treatments for autoimmune diseases, including lupus nephritis. LUPKYNIS is the first oral therapy for lupus nephritis approved by the U.S. Food and Drug Administration. Outside the U.S., Aurinia has partnered with Otsuka Pharmaceutical to commercialize the drug in Japan, Europe, and other regions. The company is also developing aritinercept, a next-generation autoimmune therapy candidate that simultaneously targets the B-cell activating factors BAFF and APRIL.